Skip to main content
    E

    Entrada Therapeutics Inc (TRDA)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $5.00
    -0.09 (-1.77%)

    Market Cap: $199.28M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Entrada Therapeutics Inc (TRDA) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Entrada Therapeutics are Arcturus Therapeutics Holdings (ARCT), Rocket Pharmaceuticals (RCKT) and Invivyd (IVVD). By market cap, Entrada Therapeutics ranks 9th of the 13 companies on this page; Enanta Pharmaceuticals (ENTA) is the largest at $320.09M.

    Peer Comparison

    TRDA's ROIC of -69.7% is below the peer median of -6.7%, and its revenue growth of -43.9% is below the median of 3.4%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Entrada Therapeutics (TRDA)$199.28MN/A53.3x0.0%-69.7%-43.9%0.00%
    Arcturus Therapeutics Holdings Inc (ARCT)$240.96MN/A7.7x-285.9%N/A6.7%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Enanta Pharmaceuticals Inc (ENTA)$320.09MN/A4.8x-96.9%N/A-21.6%0.00%
    ProQR Therapeutics BV (PRQR)$199.28MN/A6.1x-228.2%N/A120.4%0.00%
    Bicycle Therapeutics Ltd (BCYC)$236.22MN/A2.7x-169.8%N/A190.2%0.00%
    Q32 Bio Inc (QTTB)$260.64M2.5x5.2x60.0%N/A0.0%0.00%
    Fate Therapeutics Inc (FATE)$155.74MN/A29.7x0.0%-51.3%9.2%0.00%
    LENZ Therapeutics Inc (LENZ)$129.77MN/A9.7x0.0%N/A-72.9%0.00%
    Lineage Cell Therapeutics Inc (LCTX)$231.35MN/A18.7x16.2%-6.7%-61.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    Peer median$233.78M2.5x6.9x-48.5%-6.7%3.4%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Entrada Therapeutics, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Arcturus Therapeutics Holdings Inc (ARCT)
    Arcturus Therapeutics Holdings Inc., an RNA drug company, focuses on the treatment of liver and respiratory diseases.
    ARCT competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Enanta Pharmaceuticals Inc (ENTA)
    Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.
    ENTA competitors
    ProQR Therapeutics BV (PRQR)
    ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders.
    PRQR competitors
    Bicycle Therapeutics Ltd (BCYC)
    Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, is developing a class of drugs for diseases that are not served by existing treatments.
    BCYC competitors
    Q32 Bio Inc (QTTB)
    Q32 Bio Inc. (QTTB) is a pioneering biotechnology firm focused on the development of advanced antibody-based therapies for autoimmune diseases and immune...
    QTTB competitors
    Fate Therapeutics Inc (FATE)
    Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally.
    FATE competitors
    LENZ Therapeutics Inc (LENZ)
    LENZ Therapeutics Inc is a cutting-edge biopharmaceutical company dedicated to developing transformative therapies for neurological disorders...
    LENZ competitors
    Lineage Cell Therapeutics Inc (LCTX)
    Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing therapeutics for the treatment...
    LCTX competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors

    Frequently Asked Questions About TRDA

    Who are Entrada Therapeutics' main competitors?

    The companies most similar to Entrada Therapeutics include Arcturus Therapeutics Holdings (ARCT), Rocket Pharmaceuticals (RCKT), Invivyd (IVVD), Protara Therapeutics (TARA) and Enanta Pharmaceuticals (ENTA), listed from the closest match.

    Who is Entrada Therapeutics' biggest competitor?

    Enanta Pharmaceuticals (ENTA) is the largest of the similar companies at $320.09M; Arcturus Therapeutics Holdings (ARCT) is the closest match by business profile, size, sector and industry.

    How does TRDA stock compare with its competitors?

    TRDA's P/S is 53.3x against a peer median of 6.9x; its net margin is 0.0% against a peer median of -48.5%.

    Which of Entrada Therapeutics' competitors pays a higher dividend?

    Entrada Therapeutics pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Entrada Therapeutics bigger than its competitors?

    No. Entrada Therapeutics is 9th by market cap among the 13 companies on this page; the largest is Enanta Pharmaceuticals (ENTA) at $320.09M.